Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma:its clinical efficacy and safety
10.3969/j.issn.1008-794X.2024.11.011
- VernacularTitle:肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析
- Author:
Mengjie YIN
1
;
Shouzhong FU
;
Feng DAI
;
Bin WANG
;
Xiaowei WANG
;
Wei DING
;
Fengchen JIANG
;
Jiandong SHEN
Author Information
1. 226001 江苏南通 南通大学附属南通第三医院(南通市第三人民医院)介入血管科
- Keywords:
hepatocellular carcinoma;
hepatic arterial infusion chemotherapy;
safety;
curative efficacy
- From:
Journal of Interventional Radiology
2024;33(11):1212-1217
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical efficacy and safety of hepatic arterial infusion chemotherapy(HAIC)combined with carrelizumab and sorafenib in treating advanced hepatocellular carcinoma(HCC).Methods The clinical data of 36 HCC patients,who were admitted to the Affiliated Nantong Third Hospital of Nantong University of China to receive HAIC combined with carrelizumab and sorafenib from August 2019 to August 2020,were collected.According to modified Response Evaluation Criteria in Solid Tumors(mRECIST),the objective response rate(ORR)and disease control rate(DCR)of the combination therapy were evaluated.The Common Terminology Criteria Adverse Events Version 5.0 developed by American National Cancer Institute was used to evaluate the clinical safety.Results After receiving 4 cycles of FOLFOX-HAIC,the ORR and DCR of the patients were 38.9％and 77.8％respectively.The patients were followed up for 30 months.The median progression-free survival(mPFS)was 306 days(95％CI:242.7-369.3),and the median overall survival(mOS)was 515 days(95％CI:2 482.5-547.5).After HAIC treatment,one patient was successfully changed to surgical operation.The overall incidence of adverse events were 100％.There were 9 adverse events(25％)above grade m,including severe abdominal pain(n=2,5.6％),nausea(n=1,2.8％),vomiting(n=1,2.8％),elevated alanine aminotransferase(n=3,8.3％),elevated aspartate aminotransferase(n=1,2.8％),and death due to pulmonary failure caused by severe immune-induced pneumonia(n=1,2.8％).Conclusion For the treatment of advanced HCC,HAIC combined with carrelizumab and sorafenib has better ORR and DCR with controllable safety,which provides a new option for the treatment of advanced HCC.However,studies with large sample size need to be conducted before its long-term survival benefit of patients can be further validated.
